Partnerships, Licensing, Investments and M&A Deals and Trends for January 2017 in Pharmaceuticals

Publisher Name :
Date: 07-Mar-2017
No. of pages: 85
Inquire Before Buying

Partnerships, Licensing, Investments and M&A Deals and Trends for January 2017 in Pharmaceuticals

Summary

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for January 2017 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in January 2017. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.

- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

- Analysis of partnership and licensing deals based on clinical stage of development of products.

- Summary of the pharmaceutical deals globally in the six months.

- Information on the top deals happened in the pharmaceutical industry.

- Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.

- Find out the major deal performing segments for investments in your industry.

- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

- Identify companies that are aggressively looking to raise capital in the market

- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

- Identify growth segments and opportunities in each region within the industry.

- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Partnerships, Licensing, Investments and M&A Deals and Trends for January 2017 in Pharmaceuticals

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 6
2 Pharmaceuticals & Healthcare, Global, Deal Summary 10
2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, January 2017 10
2.2 Pharmaceuticals & Healthcare, Global, Major Deals, January 2017 12
2.2.1 Johnson & Johnson to Acquire Actelion for USD30 Billion 12
2.2.2 Takeda Pharma Acquires Ariad Pharma for up to USD5.2 Billion in Tender Offer 13
2.2.3 Les Laboratoires Servier Enters into Licensing Agreement with Pieris Pharma 13
2.2.4 Biogen to Enter into Licensing Agreement with Forward Pharma 14
2.2.5 Ipsen to Acquire Oncology Assets from Merrimack Pharma 15
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, January 2017 17
2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, January 2017 18
3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 19
3.1 Pharmaceuticals & Healthcare, Global, M&A, January 2017 19
3.1.1 Top M&A Deals in January 2017 20
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, August 2016 - January 2017 21
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, January 2017 22
3.2.1 Top Equity Offering Deals in January 2017 23
3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, August 2016 - January 2017 23
3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, January 2017 25
3.3.1 Top PE/VC Deals in January 2017 26
3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, January 2017 27
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, January 2017 28
3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, August 2016-January 2017 29
3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, August 2016-January 2017 30
3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, January 2017 31
3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, August 2016 - January 2017 32
3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), January 2017 33
3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, January 2017 34
3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), August 2016 - January 2017 35
3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, August 2016 - January 2017 37
3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), August 2016 - January 2017 38
3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), August 2016 - January 2017 40
4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, January 2017 41
4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, January 2017 41
4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), January 2017 42
4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), August 2016 - January 2017 43
4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), August 2016 - January 2017 44
4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), August 2016 - January 2017 45
4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), August 2016 - January 2017 47
4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, January 2017 48
4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, January 2017 49
4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, January 2017 50
5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 51
5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, January 2017 51
5.1.1 Oncology - Deals of the Month 52
5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, January 2017 54
5.2.1 Central Nervous System - Deals of the Month 55
5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, January 2017 57
5.3.1 Infectious Diseases - Deals of the Month 58
5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, January 2017 60
5.4.1 Cardiovascular - Deal of the Month 61
5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, January 2017 62
5.5.1 Immunology - Deals of the Month 63
5.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, January 2017 64
5.6.1 Gastrointestinal - Deal of the Month 65
5.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, January 2017 67
5.7.1 Metabolic Disorders - Deal of the Month 68
6 Deal Summary by Geography 69
6.1 Pharmaceuticals & Healthcare, North America Deals, January 2017 69
6.1.1 North America - Deals of the Month 70
6.2 Pharmaceuticals & Healthcare, Europe, Deals, January 2017 74
6.2.1 Europe - Deals of the Month 75
6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, January 2017 76
6.3.1 Asia-Pacific - Deals of the Month 77
6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, January 2017 79
6.4.1 Rest of the World - Deals of the Month 80
7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 81
7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, August 2016 - January 2017 81
7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, August 2016 - January 2017 82
8 Further Information 83
8.1 Methodology 83
8.2 About GlobalData 84
8.3 Contact Us 84
8.4 Disclosure information 84
8.5 Disclaimer 85

1.1 List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 11
Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, January 2017 12
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), January 2017 18
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 20
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, January 2017 20
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, August 2016 - January 2017 21
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 23
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, January 2017 23
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 24
Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 26
Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, January 2017 26
Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, August 2016 - January 2017 27
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), January 2017 29
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 30
Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, August 2016 - January 2017 30
Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 31
Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 32
Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), August 2016 - January 2017 33
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), January 2017 34
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), August 2016 - January 2017 36
Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2016 - January 2017 39
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), August 2016 - January 2017 40
Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 41
Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), August 2016 - January 2017 42
Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 43
Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), January 2017 44
Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2016 - January 2017 46
Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), January 2017 48
Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, January 2017 48
Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, January 2017 49
Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, January 2017 50
Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 52
Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 55
Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 58
Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 61
Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 63
Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 65
Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 68
Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 70
Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 75
Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 77
Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 80
Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 81
Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 82

1.2 List of Figures
Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 10
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), January 2017 17
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), January 2017 18
Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 19
Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, August 2016 - January 2017 21
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 22
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 23
Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 25
Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, August 2016 - January 2017 27
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), January 2017 28
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), January 2017 28
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 29
Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 31
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 32
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), August 2016 - January 2017 33
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), August 2016 - January 2017 35
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2016 - January 2017 37
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2016 - January 2017 38
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), August 2016 - January 2017 40
Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 41
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), August 2016 - January 2017 42
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 43
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), August 2016 - January 2017 44
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, August 2016 - January 2017 45
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), August 2016 - January 2017 46
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), January 2017 47
Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 51
Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 54
Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 57
Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 60
Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 62
Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 64
Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 67
Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 69
Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 74
Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 76
Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 79
Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 81
Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), August 2016 - January 2017 82
  • Pharmaceutical Mergers and Acquisitions Market Insights 2019, Global and Chinese Analysis and Forecast to 2024
    Published: 19-Apr-2019        Price: US 3000 Onwards        Pages: 138
    Pharmaceutical Mergers and Acquisitions Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Pharmaceutical Mergers and Acquisitions industry with a focus on the Chinese market. The report provides key statistics on the market status of the Pharmaceutical Mergers and Acquisitions manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provide......
  • Pharmerging Contract Manufacturings Market Insights 2019, Global and Chinese Analysis and Forecast to 2024
    Published: 17-Feb-2019        Price: US 3000 Onwards        Pages: 135
    Pharmerging Contract Manufacturings Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Pharmerging Contract Manufacturings industry with a focus on the Chinese market. The report provides key statistics on the market status of the Pharmerging Contract Manufacturings manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-dept......
  • Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2010-2018
    Published: 01-Oct-2018        Price: US 2995 Onwards        Pages: 344
    The Global Co-promotion and Co-marketing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2018 report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading healthcare companies. The Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2018 report provides comprehensive understanding and unprecedented access to the ......
  • Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2018
    Published: 01-Oct-2018        Price: US 1995 Onwards        Pages: 348
    The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2018 report provides comprehensive understanding and unprecedented access to the joint venture partnering agreements entered into by the worlds leading healthcare companies. The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2018 report provides comprehensive understanding and unprecedented access to the joint venture deals and agreements entered i......
  • Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2018
    Published: 01-Oct-2018        Price: US 1995 Onwards        Pages: 350
    The Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2018 report provides comprehensive understanding and unprecedented access to the royalty financing partnering agreements entered into by the worlds leading healthcare companies. The Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2018 report provides comprehensive understanding and unprecedented access to the royalty financing agreem......
  • Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012 to 2018
    Published: 01-Oct-2018        Price: US 2995 Onwards        Pages: 457
    The Global Co-development Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2012-2018 report provides comprehensive understanding and unprecedented access to the co-development deals and agreements entered into by the worlds leading healthcare companies. The Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 report provides comprehensive understanding and unprecedented access to the co-development deals and agreements entered ......
  • Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2012-2018
    Published: 01-Oct-2018        Price: US 2995 Onwards        Pages: 2000
    The Global Collaborative R&D Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2012-2018 report provides comprehensive understanding and unprecedented access to the collaborative R&D partnering deals and agreements entered into by the worlds leading healthcare companies. The Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 report provides comprehensive understanding and unprecedented access to the collaborative R&D deals an......
  • Global Academic and Non-Profit Partnering Terms and Agreements 2012-2018: Deal trends, players and financials
    Published: 01-Oct-2018        Price: US 2995 Onwards        Pages: 1000
    Global Academic and Non-Profit Partnering Terms and Agreements 2012 to 2018 report provides a detailed understanding and analysis of how and why companies enter Academic and Non-Profit partnering deals Global Academic and Non-Profit Partnering Terms and Agreements 2012 to 2018 report provides a detailed understanding and analysis of how and why companies enter Academic and Non-Profit partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to c......
  • Global Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018
    Published: 01-Sep-2018        Price: US 2995 Onwards        Pages: 1000
    "Delivery of this report will take 1-3 days after purchase." The Global Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 report provides details of the latest merger and acquisition (M&A) agreements announced in the pharmaceutical, biotechnology, diagnostic and other lifescience sectors. Fully revised and updated, the report provides details of M&A agreements from 2012 to 2018. The report provides a detailed understan......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs